Baudax Bio is a biotechnology company focused on developing and commercializing innovative products for patients in rare diseases settings. We are committed to bringing clinically meaningful therapeutic options to patients, health care providers, and payers. We believe we can create value for healthcare providers, patients and shareholders through our portfolio of products, which also includes a robust pipeline of product candidates. In addition, we continue to evaluate acquisition and in-licensing opportunities which align with our core rare disease focus.
Our product candidate pipeline includes early-stage product candidates, including recently acquired TCR Treg platform and two novel neuromuscular blocking agents (NMBAs) and a related proprietary chemical reversal agent.